Abstract
Deficient neuroplasticity has been implicated in schizophrenia and can be examined with non-invasive methods in humans. High frequency visual stimulation (HFS) induces neuroplastic changes in visual evoked potential (VEP) components, similar to the tetanizing electrical stimulation that induces synaptic long-term potentiation (LTP). While visual HFS paradigms have been used in schizophrenia, the use of a single visual stimulus has precluded demonstration of whether the plasticity effects are specific to the stimulus presented during HFS (i.e., input specific). Additionally, test-retest reliability of VEP plasticity effects, an important consideration for applications of HFS paradigms in schizophrenia clinical trials, remains unknown. Accordingly, we administered a visual HFS paradigm to 38 schizophrenia patients and 27 healthy controls at baseline and two-weeks later. VEPs were elicited by horizontal and vertical line gratings before and after HFS; only one orientation was tetanized with HFS. Using a mass univariate permutation approach, we identified an input-specific cluster across groups that was broadly distributed over parietal-occipital areas between 108 and 183 ms. However, the groups did not differ in terms of the strength of plasticity effect. The test-retest reliability of the input-specific plasticity effect was modest over two weeks, suggesting that this HFS paradigm requires further development before it could be used to track plasticity change in clinical trials. Moreover, while the current HFS paradigm induced significant input-specific neuroplasticity, it did not replicate prior studies showing deficient neuroplasticity in schizophrenia. Accordingly, demonstration of deficient visual LTP-like neuroplasticity in schizophrenia may depend on paradigm parameters that remain to be fully elucidated.
Original language | English |
---|---|
Pages (from-to) | 40-46 |
Number of pages | 7 |
Journal | Schizophrenia Research |
Volume | 212 |
DOIs | |
State | Published - Oct 2019 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2019
Funding
This work was supported by Forum Pharmaceuticals (Michael F. Green, Stephen R. Marder co-PIs), by NIMH ( MH095878 , Michael F. Green, PI), the VISN 22 Mental Illness , Research, Education, and Clinical Center (director, Stephen R. Marder), and the Research Enhancement Award Program for Community Integration in Homeless Veterans (director, Michael F. Green). Dr. McCleery is supported by a career development award from NIH ( K23MH108829 ). This material is the result of work supported with resources and the use of facilities at the Veterans Affairs Greater Los Angeles Healthcare System. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. The authors would like to thank Ana Ceci Myers, Aaron McNair, and Gabrielle Pascual for their assistance in study coordination and data collection. Dr. Green has been a consultant to AiCure, Lundbeck, and Takeda, and he is on the scientific board of Cadent. He has received research funds from FORUM. Dr. Marder has served as a consultant to Roche, Allergan, Takeda, Neurocrine, Newron, Boehringer-Ingelheim, Otsuka, Acadia, Lundbeck, and Teva. He has received research support from Neurocrine and Takeda. Dr. McCleery has received compensation from MedAvante-Prophase, Inc. for clinical assessment services unrelated to this project. Dr. Mathalon serves as a consultant for Boehringer Ingelheim and Takeda. Dr. Wynn and Mr. Roach declare no potential conflict of interest.This work was supported by Forum Pharmaceuticals (Michael F. Green, Stephen R. Marder co-PIs), by NIMH (MH095878, Michael F. Green, PI), the VISN 22 Mental Illness, Research, Education, and Clinical Center (director, Stephen R. Marder), and the Research Enhancement Award Program for Community Integration in Homeless Veterans (director, Michael F. Green). Dr. McCleery is supported by a career development award from NIH (K23MH108829). This material is the result of work supported with resources and the use of facilities at the Veterans Affairs Greater Los Angeles Healthcare System. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. The authors would like to thank Ana Ceci Myers, Aaron McNair, and Gabrielle Pascual for their assistance in study coordination and data collection.
Funders | Funder number |
---|---|
FORUM | |
FORUM Pharmaceuticals | |
Neurocrine and Takeda | |
Teva | |
United States Government | |
Veterans Affairs Greater Los Angeles Healthcare System | |
National Institutes of Health | |
National Institute of Mental Health | MH095878, K23MH108829 |
NIH Clinical Center | |
U.S. Department of Veterans Affairs | |
Roche | |
Allergan Foundation | |
Takeda Pharmaceuticals U.S.A. | |
ACADIA Pharmaceuticals | |
FORUM Pharmaceuticals | |
H. Lundbeck A/S |
Keywords
- EEG
- Schizophrenia
- VEP
- Visual neuroplasticity